ACC 2024 | PREVENT Study

The use of intravascular imaging to identify vulnerable plaque (VP) has proven to be very useful, as such plaque is associated with an increase in major adverse cardiac events. Optimal medical treatment is currently considered the standard strategy to stabilize VP. However, the safety and effectiveness of preventive treatment with percutaneous coronary intervention (PCI) in VP are still unclear.

ACC 2024

The aim of this randomized controlled study was to evaluate whether preventive PCI of VP improves clinical outcomes compared with medical treatment alone.

The primary endpoint (PEP) was target-vessel failure (TVF), defined as a set of events including death from cardiac causes, myocardial infarction related to the treated vessel, ischemia-driven target-vessel revascularization, or hospitalization for unstable or progressive angina after 2 years of randomization. VP lesions to be assessed were defined as coronary stenosis greater than 50% with negative coronary fraction flow reserve (FFR) (≥0.80) along with two of the following criteria: minimum luminal area (MLA) ≤4 mm2, plaque volume >70%, presence of thin-cap fibroatheroma identified through optical coherence tomography (OCT) or intravascular ultrasound (IVUS), and presence of lipid-rich plaque identified by near-infrared spectroscopy (NIRS).

Read also: ACC 2024 | DanGer-Shock Trial.

A total of 1600 patients were analyzed; 800 of them were randomized to the medical treatment alone group and 800 to the preventive PCI plus medical treatment group. Regarding the PFP, the preventive PCI plus medical treatment group had a lower cumulative incidence of TVF at 2 years compared with the medical treatment alone group (preventive PCI 0.4% vs. medical treatment 3.4%; hazard ratio [HR] 0.11 [95% confidence interval (CI) 0.03-0.36], p=0.0003). These results were sustained at 7 years of follow-up, with a lower incidence of TVF in the preventive PCI group (6.5%) compared with the medical treatment alone group (9.4%): HR 0.54 [95% CI 0.33-0.87], p=0.0097.

Conclusions

In conclusion, in this study, preventive PCI along with medical treatment resulted in a lower incidence of major adverse cardiac events compared with medical treatment alone in VP lesions that did not limit coronary flow.

Dr. Andrés Rodríguez.
Member of the Editorial Board of SOLACI.org.

Original Title: PREVENT Preventive PCI versus Medical Therapy Alone for Treatment of Vulnerable Atherosclerotic Coronary Plaques.

Reference: Seung-Jung Park et al. 


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

CRABBIS Trial: Comparison of Different Provisional Stenting Sequences

Provisional stenting (PS) is the gold standard for percutaneous coronary intervention (PCI) in most patients with coronary bifurcation lesions (CBL). Moreover, recent studies such...

Andromeda Trial: Meta-Analysis of Drug Coated Balloon vs. DES in Small Vessel DeNovo Lesions

The use of coronary stents vs plain old balloon angioplasty (POBA), has allowed to reduce recoil and limiting flow dissection which were major limitation...

QFR vs. FFR: Is Coronary Revascularization Deferral Safe? Results from a FAVOR III Sub-Analysis

In cases of intermediate coronary lesions, functional assessment is recommended to aid the decision-making process regarding revascularization. There are several tools currently used to...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2025 | FAME 3: FFR Guided PCI vs CABG 5 Year Outcomes.

Earlier studies comparing percutaneous coronary intervention (PCI) vs coronary artery bypass graft (CABG) have shown fewer events at long term for the surgical strategy.  However,...

ACC 2025 | API-CAT: Reduced vs. Full Dose Extended Anticoagulation in Patients with Cancer Related VTE

The risk of cancer related recurrent venous thromboembolism (VTE) will drop over time, while bleeding risk will persist. At present, it is recommended we...

STRIDE: Semaglutide in Patients with Peripheral Arterial Disease and Type II Diabetes

Peripheral arterial disease (PAD) is a severe complication in patients with type II diabetes, primarily affecting peripheral vessels, especially below-the-knee (BTK) arteries. This condition...